对Mark Litt博士评论的回应。

IF 3.2 3区医学 Q1 Medicine Alcoholism, clinical and experimental research Pub Date : 2019-08-26 DOI:10.1111/acer.14160

R. Anton, K. Witkiewitz, Daniel E. Falk, R. Litten, D. Hasin, K. Mann, S. O'Malley

{"title":"对Mark Litt博士评论的回应。","authors":"R. Anton, K. Witkiewitz, Daniel E. Falk, R. Litten, D. Hasin, K. Mann, S. O'Malley","doi":"10.1111/acer.14160","DOIUrl":null,"url":null,"abstract":"We wish to thank Dr. Mark Litt for his very thoughtful and comprehensive commentary (Litt 2019) on our body of work describing the potential use of the World Health Organization (WHO) risk drinking levels (World Health Organization, 2000) for judging success/efficacy in clinical trials generally, but in pharmacotherapy trials in particular. Importantly, Dr. Litt highlights the importance of this work for clinical practice. He rightly describes the issue that many clinicians face, the fact that many treatment-seekers do not desire complete abstinence, both because it is a goal that is difficult to achieve and because many social situations that involve alcohol can be difficult to navigate for non-drinkers. This article is protected by copyright. All rights reserved.","PeriodicalId":7410,"journal":{"name":"Alcoholism, clinical and experimental research","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2019-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Response to Dr. Mark Litt's Commentary.\",\"authors\":\"R. Anton, K. Witkiewitz, Daniel E. Falk, R. Litten, D. Hasin, K. Mann, S. O'Malley\",\"doi\":\"10.1111/acer.14160\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We wish to thank Dr. Mark Litt for his very thoughtful and comprehensive commentary (Litt 2019) on our body of work describing the potential use of the World Health Organization (WHO) risk drinking levels (World Health Organization, 2000) for judging success/efficacy in clinical trials generally, but in pharmacotherapy trials in particular. Importantly, Dr. Litt highlights the importance of this work for clinical practice. He rightly describes the issue that many clinicians face, the fact that many treatment-seekers do not desire complete abstinence, both because it is a goal that is difficult to achieve and because many social situations that involve alcohol can be difficult to navigate for non-drinkers. This article is protected by copyright. All rights reserved.\",\"PeriodicalId\":7410,\"journal\":{\"name\":\"Alcoholism, clinical and experimental research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2019-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alcoholism, clinical and experimental research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/acer.14160\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alcoholism, clinical and experimental research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/acer.14160","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

我们要感谢Mark Litt博士对我们的工作进行了非常周到和全面的评论(Litt 2019)，该评论描述了世界卫生组织(世卫组织)风险饮酒水平(世界卫生组织，2000年)在一般临床试验(特别是药物治疗试验)中判断成功/疗效的潜在用途。重要的是，Litt博士强调了这项工作对临床实践的重要性。他正确地描述了许多临床医生面临的问题，即许多寻求治疗的人并不希望完全戒酒，一方面是因为这是一个难以实现的目标，另一方面是因为许多涉及酒精的社交场合对不饮酒者来说很难驾驭。这篇文章受版权保护。版权所有。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Response to Dr. Mark Litt's Commentary.

We wish to thank Dr. Mark Litt for his very thoughtful and comprehensive commentary (Litt 2019) on our body of work describing the potential use of the World Health Organization (WHO) risk drinking levels (World Health Organization, 2000) for judging success/efficacy in clinical trials generally, but in pharmacotherapy trials in particular. Importantly, Dr. Litt highlights the importance of this work for clinical practice. He rightly describes the issue that many clinicians face, the fact that many treatment-seekers do not desire complete abstinence, both because it is a goal that is difficult to achieve and because many social situations that involve alcohol can be difficult to navigate for non-drinkers. This article is protected by copyright. All rights reserved.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Alcoholism, clinical and experimental research 医学-药物滥用

CiteScore

5.90

自引率

9.40%

发文量

219

审稿时长

1 months

期刊介绍： Alcoholism: Clinical and Experimental Research''s scope spans animal and human clinical research, epidemiological, experimental, policy, and historical research relating to any aspect of alcohol abuse, dependence, or alcoholism. This journal uses a multi-disciplinary approach in its scope of alcoholism, its causes, clinical and animal effect, consequences, patterns, treatments and recovery, predictors and prevention.